Short interest for iRadimed gives investors a sense of the degree to which investors are betting on the decline of iRadimed's stock. Short interest data is updated every two weeks.

iRadimed Stock (NASDAQ:IRMD), Short Interest Report

iRadimed

iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.

News

Short Ideas

Small Cap

Insider Trades

Pre-Market Outlook

Markets

Trading Ideas

IRMD

NTAP

The Nasdaq 100 closed lower by more than 50 points on Thursday. Investors, meanwhile, focused on some notable insider trades.

Caleres, Cloudflare And 2 Other Stocks Insiders Are Selling

Health Care

General

Iradimed Notifies Potential Issue With Certain Syringe Adapter Sets During Use

Iradimed Withdraws FDA Application For Updated MR IV Pump System

iRadimed Corp

Biotech

Earnings

Guidance

IRADIMED Expects Q2 Adjusted EPS Of $1.52-$1.62 Versus Consensus Of $1.38

IRADIMED Expects 2024 Revenues Of $72M-$74M Versus Consensus Of $72.56M

IRADIMED Expects Q2 Adjusted EPS Of $0.36 to $0.39 Versus Consensus Of $0.35

IRADIMED Expects Q2 Revenues Of $17.6M-$17.8M Versus Consensus Of $17.88M

<p>iRadimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRMD#NASDAQ">IRMD</a>) reported quarterly earnings of $0.36 per share which beat the analyst consensus estimate of $0.34 by 5.88 percent. This is a 20 percent increase over earnings of $0.30 per share from the same period last year.  The company reported quarterly sales of $17.598 million which beat the analyst consensus estimate of $17.130 million by 2.73 percent.  This is a 13.72 percent increase over sales of $15.475 million the same period last year.</p>


Earnings Beats

iRadimed Q1 2024 Adj EPS $0.36 Beats $0.34 Estimate, Sales $17.598M Beat $17.130M Estimate

<p>Roth MKM  analyst Jason Wittes   reinstates iRadimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRMD#NASDAQ">IRMD</a>) with a Buy and announces $65 price target.</p>


Price Target

Initiation

Analyst Ratings

Roth MKM Reinstates Buy on iRadimed, Announces $65 Price Target

Offerings

Iradimed Corp Files For Offering Of Common Stock Of Up To $75M

IRadimed Forecasts FY24 Revenue of $72M-$74M, With Adjusted EPS Of $1.52-$1.62 Compared To Consensus Of $71.50M And $1.48, Respectively

IRadimed Forecasts Q1 FY24 Revenue of $17M-$17.3M, With Adjusted EPS Of $0.33-$0.35 Compared To Consensus Of $16.50M And $0.32, Respectively

<p>iRadimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRMD#NASDAQ">IRMD</a>) reported quarterly earnings of $0.39 per share which missed the analyst consensus estimate of $0.40 by 2.5 percent. This is a 21.88 percent increase over earnings of $0.32 per share from the same period last year.  The company reported quarterly sales of $17.45 million which beat the analyst consensus estimate of $17.33 million by 0.70 percent.  This is a 17.42 percent increase over sales of $14.86 million the same period last year.</p>


iRadimed Q4 Adjusted EPS $0.39 Misses $0.40 Estimate, Sales $17.45M Beat $17.33M Estimate

AFRM

AIRC

APDN

ARES

AXTA

BILL

BIOX

CIGI

CIVB

CLSK

CPRI

CRIS

CTLP

CTRE

CYBR

DOCS

DXCM

EGAN

EMKR

EXPE

FARM

FLUX

FORR

GTES

IBEX

IIIV

ILMN

JRSH

KVUE

LADR

LITE

LIVE

LPTH

LQDT

LSPD

LTRX

LVWR

NGVC

OMCL

ONTO

PATK

PCTY

PEAK

PECO

PETS

PINE

PINS

PODC

Earnings Scheduled For February 8, 2024

<p><strong>iRadimed</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRMD#NASDAQ">IRMD</a>) is set to give its latest quarterly earnings report on Thursday, 2024-02-08. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that iRadimed will report an <strong>earnings per share</strong> (EPS) of $0.40. </p>
<p>iRadimed bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Historical Earnings Performance</h3>
<p>Last quarter the company beat EPS by $0.07, which was followed by a 0.0% drop in the share price the next day.</p>
<p>Here's a look at iRadimed's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2023</strong></th>
<th><strong>Q2 2023</strong></th>
<th><strong>Q1 2023</strong></th>
<th><strong>Q4 2022</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.36</td>
<td>0.31</td>
<td>0.28</td>
<td>0.30</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.43</td>
<td>0.36</td>
<td>0.30</td>
<td>0.32</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>9.9%</td>
<td>0.46%</td>
<td>1.34%</td>
<td>-2.09%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1707328929_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of iRadimed were trading at $45.77 as of February 06. Over the last 52-week period, shares are up 27.7%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/IRMD/earnings"><strong>To track all earnings releases for iRadimed visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


iRadimed's Earnings Outlook

<ul>
<li>Reports preliminary fourth quarter 2023 revenue of $17.5 million<br /><br />&nbsp;</li>
</ul>
<p>WINTER SPRINGS, Fla., Jan. 09, 2024 (GLOBE NEWSWIRE) -- &nbsp;IRADIMED CORPORATION (the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRMD#NASDAQ">IRMD</a>), a leader in developing innovative Magnetic Resonance Imaging (‘MRI") compatible medical devices, today reported unaudited revenue for the fourth quarter and fiscal year ended December 31, 2023. The fourth-quarter revenue totaled approximately $17.5 million, bringing revenue for 2023 to approximately $65.6 million, up 23% from the prior year.</p>
<p>"We are very pleased to announce these fourth quarter 2023 preliminary results, which is our highest quarterly revenue ever and continues our string of ten consecutive quarters of record revenues. The value of our products continues to resonate with our customers as we see growing demand for our products and expect this to continue through 2024," said Roger Susi, President and Chief Executive Officer of the Company.</p>


IRADIMED CORPORATION Reports Unaudited Q4 Revenue $17.5M Vs $17.13M Est.; FY23 Revenue $65.6M Vs $65.07M Est.

<p>Wednesday marks the last chance for investors to receive the next  dividend payout from <strong>iRadimed</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRMD#NASDAQ">IRMD</a>). </p>
<h3>What's Happening</h3>
<p>The company announced on Tuesday that it would pay shareholders a quarterly dividend of 15 cents per share. On Thursday, iRadimed will go ex-dividend, meaning the stock will trade lower to reflect that payout. In other words, the stock will likely open 15 cents lower than it would have opened on any other day.</p>
<p>In order to be eligible to receive a company's dividend, shareholders must own the stock prior to the ex-dividend date—in this case, Thursday. Shareholders who own IRMD as of the end of Wednesday's session are eligible to receive the 15 cents dividend payout for every share that they own. </p>
<p>According to the company, this dividend will be paid out to shareholders on January 12, 2024. Investors will then be able to either reinvest those dividends back into the stock or use the payment in some other way. </p>
<p><a href="https://www.benzinga.com/stock//dividends">Click here</a> to find details on iRadimed's previous dividends.</p>
<p>To keep track of which companies are distributing dividends, <a href="https://www.benzinga.com/calendars/dividends">click here</a> to visit our Dividends Calendar.  </p>


Dividends

Wednesday Is Your Last Chance To Buy iRadimed Before The Dividend Payout

WIIM

IRADIMED shares are trading higher after the company reported better-than-expected Q3 financial results and issued Q4 adjusted EPS guidance above estimates. Also, the company issued FY23 guidance above estimates.

IRADIMED Sees FY23 Adjusted EPS Of $1.48-$1.51 Versus Consensus Of $1.26 And Prior Range Of $1.37-$1.40

IRADIMED Sees FY23 Revenue Of $65.0M-$65.5M Versus Consensus Of $64.77M And Prior Range Of $64.5M-$65.5M

IRADIMED Sees Q4 FY23 Adjusted EPS Of $0.38-$0.41 Versus Consensus Of $0.33

IRADIMED Sees Q4 FY23 Revenue Of $16.9M-$17.4M Versus Consensus Of $17.01M

<p>iRadimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRMD#NASDAQ">IRMD</a>) reported quarterly earnings of $0.43 per share which beat the analyst consensus estimate of $0.36 by 19.44 percent. This is a 48.28 percent increase over earnings of $0.29 per share from the same period last year.  The company reported quarterly sales of $16.50 million which beat the analyst consensus estimate of $16.17 million by 2.07 percent.  This is a 23.10 percent increase over sales of $13.41 million the same period last year.</p>


iRadimed Q3 Adjusted EPS $0.43 Beats $0.36 Estimate, Sales $16.50M Beat $16.17M Estimate

IRADIMED files to offer common stock

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alcon (ALC – Research Report) and Iradimed (IRMD – R...

Analysts Offer Insights on Healthcare Companies: Alcon (ALC) and Iradimed (IRMD)

iRadimed resumed at Roth MKM as a buy as only provider of MRI-compatible IV pumps

In a report released today, Frank Takkinen from Lake Street reiterated a Buy rating on Iradimed (IRMD – Research Report), with a price target of $6...

Iradimed (IRMD) Gets a Buy from Lake Street

iRadimed Q1 2024 Earnings Preview

Notable earnings before Thursday's open

iRadimed declares $0.15 dividend

iRadimed Non-GAAP EPS of $0.36 beats by $0.02, revenue of $17.6M beats by $0.47M

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>iRadimed</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/irmd-stock-quote/"><strong>IRMD</strong></a></span>) just reported results for the first quarter of 2024.</p><ul><li>iRadimed reported earnings per share of 36 cents. This was above the analyst estimate for EPS of 33 cents.</li><li>The company reported revenue of $17.60 million.</li><li>This was 2.73% better than the analyst estimate for revenue of $17.13 million.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/05/irmd-stock-earnings-iradimed-for-q1-of-2024/">IRMD Stock Earnings: iRadimed Beats EPS, Beats Revenue for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

IRMD Stock Earnings: iRadimed Beats EPS, Beats Revenue for Q1 2024

IRADIMED CORPORATION (IRMD) Q1 2024 Earnings Call Transcript

ABUS

ACDVF

ACLLF

AGCO

AGIO

ALNY

AMKBY

APPN

APTV

ARHS

ATGFF

ATUS

AUPH

AVNS

AXGN

BPMC

BRKR

CCRD

CDUAF

CGNX

CNHI

CPSH

CRTO

DNNGY

DRVN

EDVMF

ENOV

EXLS

FLWS

FTDR

GERN

GMAB

HIPO

IDCC

INMD

ITRI

Press Releases

IRADIMED CORPORATION Announces Third Quarter 2023 Financial Results

IRADIMED CORPORATION Named a 2024 Most Successful Small-Cap Company in America by Forbes

IRADIMED CORPORATION Announces Establishment of a Quarterly Dividend of $0.15 per share and a Special Cash Dividend of $0.48 per share

IRADIMED CORPORATION To Present at the 42nd Annual J.P. Morgan Healthcare Conference

IRADIMED CORPORATION Reports Unaudited Fourth Quarter and 2023 Revenue

IRADIMED CORPORATION to Hold 2023 Fourth Quarter Financial Results Conference Call on February 8th.

IRADIMED CORPORATION Announces Fourth Quarter of 2023 and Full Year of 2023 Financial Results

IRADIMED CORPORATION To Participate at the 36th Annual Roth Conference

IRADIMED CORPORATION to Hold 2024 First Quarter Financial Results Conference Call on May 2nd

IRADIMED CORPORATION Announces First Quarter of 2024 Financial Results and the Declaration of its Regular Quarterly Cash Dividend of $0.15 Per Share

Artivion

Alphatec Holdings

AtriCure

Axogen

EDAP TMS S.A. - American Depositary Shares, each representing One Ordinary Share

-

-

-

-

-

-

-

-

-

-

-

-

-

-

iRadimed Stock (NASDAQ:IRMD), Short Interest Report

People Also Watch